Dark Mode
More forecasts: Johannesburg 14 days weather
  • Monday, 15 July 2024

FDA Approves World's First Chikungunya Vaccine to Combat Emerging Global Health Threat

FDA Approves World's First Chikungunya Vaccine to Combat Emerging Global Health Threat

In a significant breakthrough, the U.S. Food and Drug Administration (FDA) has approved Ixchiq, the world's first chikungunya vaccine developed by Valneva. This single-dose, live formulation aims to prevent disease caused by the chikungunya virus (CHIKV) in individuals aged 18 and older who are at an increased risk of exposure.


What is Chikungunya?

Chikungunya, a mosquito-borne disease, has been recognized as an "emerging global health threat," with over 5 million reported cases in the past 15 years. This year alone, approximately 440,000 cases, including 350 deaths, have been reported. The highest risk areas include tropical and subtropical regions of Africa, Southeast Asia, and parts of the Americas. 


The most common symptoms of chikungunya, such as fever and joint pain, can be severe, leading to prolonged health problems, particularly in older adults and individuals with underlying medical conditions. The FDA's approval of Ixchiq is a vital advancement in the prevention of a potentially debilitating disease that currently lacks specific treatment options.


The Vaccine

Ixchiq is administered as a single dose by injection into the muscle and contains a live, weakened version of the chikungunya virus. The FDA's evaluation, based on immune response data from clinical studies with approximately 3,500 participants, led to the vaccine's approval under the Accelerated Approval pathway. This pathway allows approval for serious or life-threatening conditions based on evidence of a product's effectiveness that is reasonably likely to predict clinical benefit.


While the vaccine demonstrated positive results in clinical trials, it is not without side effects. Headache, fatigue, muscle pain, joint pain, fever, nausea, and tenderness at the injection site were reported as the most common side effects. Some recipients experienced severe chikungunya-like adverse reactions, although not commonly reported, emphasising the need for continued postmarketing studies to assess the vaccine's safety.


With this approval, Ixchiq becomes the world's first licensed chikungunya vaccine, marking a crucial step in addressing the global health threat posed by the virus. The FDA's decision is expected to accelerate the vaccine's global rollout, offering hope in the fight against chikungunya.

Comment / Reply From